

Special Issue

The Development of Recombinant and Subunit Vaccines Against Infectious Diseases

Message from the Guest Editor

While significant progress has been made in preventing and controlling infectious diseases globally, humanity continues to suffer from their devastating effects. Vaccines play a crucial role in combating infectious diseases. Many successful vaccines have been developed to immunize against human infectious diseases, thereby reducing morbidity and mortality. One strategy for developing new and more effective vaccines involves using immunogenic proteins in the form of recombinant vaccines. However, recombinant proteins are generally weak antigens and necessitate appropriate adjuvants and delivery systems to enhance their protective efficacy. Incorporating adjuvants can reduce the antigens required to elicit an optimal immune response, thereby minimizing adverse effects at the inoculation site. This Special Issue invites original research and review articles on the efficacy of adjuvanted recombinant vaccines in preclinical and clinical trials against bacterial, parasitic, fungal, and viral infections for consideration.

Guest Editor

Prof. Dr. Abu Salim Mustafa

Department of Microbiology, College of Medicine, Health Sciences Centre, Kuwait University, Kuwait City, Kuwait

Deadline for manuscript submissions

31 October 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/209831

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).